Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5)

Family Practice

Volumn 24, Issue 6, 2007, Pages 529-531

  Logtenberg, S J J ^a   Kleefstra, N ^a,b   Ubink Veltmaat, L J ^c   Houweling, S T ^b   Bilo, H J G ^a,d  

^a ISALA HOSPITAL   (Netherlands)

^b LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

^c University of Groningen ^*

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cell failure; Insulin resistance; Primary health care; Therapy; Type 2 diabetes mellitus

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CORRELATIONAL STUDY; DIABETIC DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; FEMALE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PANCREAS DISEASE; PANCREAS ISLET BETA CELL; PATIENT INFORMATION; PRESCRIPTION; PRIMARY MEDICAL CARE; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; NATIONAL HEALTH PROGRAMS; NETHERLANDS; PRIMARY HEALTH CARE; TIME FACTORS;

EID: 37749030173     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmm064     Document Type: Article

References (9)

1. Rutten GEHM, De Grauw WJC, Nijpels G, et al. Dutch college of general practitioners. Guidelines on type 2 diabetes, second revision (in Dutch). Huisarts Wet 2006; 49: 137-152.
2. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
3. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes. Insulin resistance and beta-cell function. Diabetes 2004; 53: S34-S38.
4. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540.
5. Tanenberg RJ. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes. Curr Med Res Opin 2004; 20: 541-553.
6. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001; 24: 89-94.
7. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: A prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003; 18: 793-800.
8. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32: 24-34.
9. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006; 23: 516-521.